Alliqua, Celgene ink licensing agreement

Wednesday, November 20, 2013

Alliqua, a biopharmaceutical company focused on the development, manufacturing and distribution of proprietary transdermal wound care and drug delivery technologies, entered into a licensing agreement with Celgene Cellular Therapeutics (CCT), a subsidiary of Celgene, whereby Alliqua received the right to develop and market the advanced wound care products Biovance and Extracellular Matrix (ECM).

[Read More]